Drug Profile
Research programme: Clostridium difficile monoclonal antibodies - XBiotech
Latest Information Update: 15 Sep 2022
Price :
$50
*
At a glance
- Originator XBiotech
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Clostridium difficile infections
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA (PO)
- 16 Mar 2017 Preclinical trials in Clostridium difficile infections in USA (PO), before March 2017
- 26 Oct 2015 Early research in Clostridium difficile infections in USA (PO)